On October 21st, Sanofi released a statement stating that it has partnered with US private equity firm Clayton Dubilier&Co; Rice（CD& R) Exclusive negotiations have been initiated for the potential sale of a 50% controlling stake in the consumer health department Opella, and the transaction is expected to be completed as early as the second quarter of next year.
The statement states that Opella's valuation is based on an enterprise value of approximately 16 billion euros. The French National Investment Bank is expected to participate as a minority shareholder, holding approximately 2% of Opella's shares.
Sanofi stated that it will continue to support Opella's future growth as a significant shareholder.